Liarozole
CAS No. 115575-11-6
Liarozole( R75251 dihydrochloride )
Catalog No. M23335 CAS No. 115575-11-6
Liarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 178 | In Stock |
|
| 10MG | 295 | In Stock |
|
| 25MG | 502 | In Stock |
|
| 50MG | 709 | In Stock |
|
| 100MG | 1008 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLiarozole
-
NoteResearch use only, not for human use.
-
Brief DescriptionLiarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).
-
DescriptionLiarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).Liarozole dihydrochloride is an imidazole derivative;?it is being investigated as a non-hormonal agent in prostate cancer and in the treatment of various other cancers and skin disorders.?(In Vitro):Liarozole (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation.Liarozole (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis.(In Vivo):Liarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation.Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially.
-
In VitroLiarozole (0.01~10 μM; 9 days; MCF-7 cells) inhibits cells proliferation.Liarozole (1 μM; 4 days; mesenchymal cells) completely inhibits chondrogenesis. Cell Proliferation Assay Cell Line:MCF-7 cells Concentration:0.01~10 μM Incubation Time:9 days Result:Had an effect of 35% inhibition at 10 μM on cell proliferation.Cell Differentiation Assay Cell Line:Mesenchymal cells Concentration:1 μM Incubation Time:4 days Result:Completely inhibited chondrogenesis.
-
In VivoLiarozole (5-20 mg/kg; p.o.; 3 days) reverses the vaginal keratosis caused by estrogen stimulation.Liarozole (40 mg/kg; p.o.; 21 days) reduces tumor burden substantially. Animal Model:Ovariectomized rats Dosage:5~20 mg/kg Administration:P.o.; 3 days Result:Reversed the vaginal keratosis caused by estrogen stimulation.Animal Model:SCID miceDosage:40 mg/kg Administration:P.o.; 21 days Result:Inhibited tumor growth and survival.
-
SynonymsR75251 dihydrochloride
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
RecptorCYP450
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number115575-11-6
-
Formula Weight308.76
-
Molecular FormulaC17H13ClN4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESClC1=CC(C(C2=CC=C3NC=NC3=C2)N4C=CN=C4)=CC=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bryson HM, et al. Liarozole. Drugs Aging. 1996 Dec;9(6):478-84; discussion 485.
molnova catalog
related products
-
CDD3506
CDD3506 increases high-density lipoprotein cholesterol by targeting hepatic CYP3A.
-
Ginsenoside F1
Ginsenoside F1,an enzymatically modified derivative of ginsenoside Rg1, protection from ultraviolet-B-induced apoptosis is tightly correlated with ginsenoside-F1-mediated inhibition of ultraviolet-B-induced downregulation of Bcl-2 and Brn-3a expression.
-
1-Aminobenzotriazole
1-Aminobenzotriazole (ABT) is a non-specific cytochrome P450 (CYP) inhibitor.
Cart
sales@molnova.com